These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 31785437)
61. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
62. A 63 signature genes prediction system is effective for glioblastoma prognosis. Zhang Y; Xu J; Zhu X Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370 [TBL] [Abstract][Full Text] [Related]
63. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma. Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952 [TBL] [Abstract][Full Text] [Related]
64. Tumor Purity as an Underlying Key Factor in Glioma. Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819 [No Abstract] [Full Text] [Related]
65. Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of Wang H; Wang X; Xu L; Zhang J; Cao H Front Oncol; 2021; 11():551160. PubMed ID: 33959491 [No Abstract] [Full Text] [Related]
66. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients. Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408 [TBL] [Abstract][Full Text] [Related]
67. The Prognostication Potential of BRCA Genes Expression in Gliomas: A Genetic Survival Analysis Study. Meimand SE; Pour-Rashidi A; Shahrbabak MM; Mohammadi E; Meimand FE; Rezaei N World Neurosurg; 2022 Jan; 157():e123-e128. PubMed ID: 34607064 [TBL] [Abstract][Full Text] [Related]
68. RGS16 promotes glioma progression and serves as a prognostic factor. Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728 [TBL] [Abstract][Full Text] [Related]
69. Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. Chen H; Xu C; Yu Q; Zhong C; Peng Y; Chen J; Chen G J Cell Physiol; 2021 Apr; 236(4):2988-3000. PubMed ID: 32964440 [TBL] [Abstract][Full Text] [Related]
70. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773 [TBL] [Abstract][Full Text] [Related]
71. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma. Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363 [TBL] [Abstract][Full Text] [Related]
72. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236 [TBL] [Abstract][Full Text] [Related]
73. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. Park SY; Piao Y; Jeong KJ; Dong J; de Groot JF Mol Cancer Ther; 2016 Sep; 15(9):2187-97. PubMed ID: 27307601 [TBL] [Abstract][Full Text] [Related]
74. Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma. Shan E; Cao YN; Zhang Y; Chen W; Ren X; Zhu S; Xi X; Mu S; Ma M; Zhi T; Li X BMC Cancer; 2023 Sep; 23(1):846. PubMed ID: 37697240 [TBL] [Abstract][Full Text] [Related]
75. Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas. Huang SP; Chiou J; Jan YH; Lai TC; Yu YL; Hsiao M; Lin YF Biochem Biophys Res Commun; 2018 Jun; 501(3):619-627. PubMed ID: 29729273 [TBL] [Abstract][Full Text] [Related]
76. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients. Liu Z; Shen F; Wang H; Li A; Wang J; Du L; Liu B; Zhang B; Lian X; Pang B; Liu L; Gao Y Cell Cycle; 2020 Jul; 19(13):1632-1640. PubMed ID: 32436804 [TBL] [Abstract][Full Text] [Related]
77. The landscape of the mesenchymal signature in brain tumours. Behnan J; Finocchiaro G; Hanna G Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477 [TBL] [Abstract][Full Text] [Related]
78. Identification of Four Enhancer-Associated Genes as Risk Signature for Diffuse Glioma Patients. Wang J; Ma X; Ma J J Mol Neurosci; 2022 Feb; 72(2):410-419. PubMed ID: 34462884 [TBL] [Abstract][Full Text] [Related]
79. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
80. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D Front Immunol; 2022; 13():773264. PubMed ID: 35185876 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]